Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response of ALK tree AIT (Itulazax) in Birch Pollen Allergy
NCT01675791Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Aug 2012
- Primary completion
- Jul 2013
- Modality
- Allergy Immunotherapy
- Countries
- 2
01
Overview
A Phase 2 trial of allergenic extract of birch in birch pollen allergy, sponsored by ALK-Abelló. Started Aug 2012; status: completed.
02
Drugs
allergenic extract of birch
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT01675791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01675791.